health biotech news today obesity drugs glp-1 Novartis, Alector, Merck, Alnylm, UniQure : Readout Newsletter How to Invest in GLP-1
Description
OFarrell M, Almohaileb FI, le Roux CW
8f, Supplementary Fig
The Phase 2 trial used a relatively rapid bi-weekly dose escalation that may have contributed to higher GI event rates
Starting a GLP-1 drug (short for glucagon-like peptide-1 receptor agonists), such as semaglutide or tirzepatide, often comes with ups and downs
Efficacy and Safety of Dulaglutide Monotherapy Compared With Glimepiride in East-Asian Patients With Type 2 Diabetes in a Multicentre, Double-Blind, Randomized, Parallel-Arm, Active Comparator, Phase III Trial
The positive effect of the structured intervention on sleep deepens the significance of the U.S
